LECTRA: Second Quarter and First Half 2025 financial report available
Paris, July 24, 2025 – Lectra informs its shareholders, in compliance with Article 221-4-IV of the General Regulation of the Autorité des marchés financiers, that the Management Discussion and Analysis of Financial Condition and Results of Operations for the Second Quarter and First Half of 2025 is available on the company's website: www.lectra.com
It is also available, upon request, at the company's headquarters 16-18 rue Chalgrin, 75016 Paris (email: investor.relations@lectra.com ).
Copy of this document was filed with the AMF.
About Lectra : At the forefront of innovation since its founding in 1973, Lectra provides industrial intelligence technology solutions—combining software in SaaS mode, cutting equipment, data, and associated services—to players in the fashion, automotive and furniture industries. With boldness and passion, Lectra accelerates the transformation and success of its customers in a world in perpetual motion thanks to the key technologies of Industry 4.0: AI, big data, cloud and the Internet of Things. The Group is present in more than one hundred countries. It operates three production sites for its cutting equipment, located in France, China and the United States. Lectra's 3,000 employees are driven by three core values: being open-minded thinkers, trusted partners and passionate innovators. They all share the same concern for social responsibility, which is one of the pillars of Lectra's strategy to ensure its sustainable growth and that of its customers. Lectra reported revenues of €527 million in 2024, including €77 million coming from its SaaS offerings. The company is listed on Euronext, and is included in the CAC All Shares, CAC Technology, EN Tech Leaders and ENT PEA-PME 150 indices. For more information, please visit lectra.com.
Lectra – World Headquarters et siège social : 16–18, rue Chalgrin • 75016 Paris • France Tél. +33 (0)1 53 64 42 00 – lectra.com Société anonyme au capital de 37 966 274 €. RCS Paris B 300 702 305
Attachment
LECTRA_PR_reportavailable_FH2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
EU chief von der Leyen heads to Scotland for trade talks with Trump
By Andrew Gray and Andrea Shalal BRUSSELS/EDINBURGH (Reuters) -EU Commission President Ursula von der Leyen headed to Scotland on Saturday ahead of a meeting with U.S. President Donald Trump on Sunday afternoon, commission spokespeople said, as EU officials said the two sides were nearing a trade agreement. Trump, in Scotland for a few days of golfing and bilateral meetings, told reporters upon his arrival on Friday evening that he was looking forward to meeting with von der Leyen, calling her a "highly respected" leader. He repeated his view that there was a 50-50 chance that the U.S. and the 27-member European Union could reach a framework trade pact, adding that Brussels wanted to "make a deal very badly". If it happened, he said it would be the biggest trade agreement reached yet by his administration, surpassing the $550 billion accord agreed with Japan earlier this week. The White House has released no details about the planned meeting or the terms of the emerging agreement. The European Commission on Thursday said a negotiated trade solution with the United States was within reach, even as EU members voted to approve counter-tariffs on 93 billion euros ($109 billion) of U.S. goods in case the talks collapse. To get a deal, Trump said the EU would have to "buy down" that tariff rate, although he gave no specifics. EU diplomats say a possible deal between Washington and Brussels would likely include a broad 15% tariff on EU goods imported into the U.S., mirroring the U.S.-Japan deal, along with a 50% tariff on European steel and aluminum. The broad tariff rate would be half the 30% duties that Trump has threatened to slap on EU goods from August 1. It remains unclear if Washington will agree to exempt the EU from sectoral tariffs on automobiles, pharmaceuticals and other goods that have already been announced or are pending. Combining goods, services and investment, the EU and the United States are each other's largest trading partners by far. The American Chamber of Commerce in Brussels warned in March that any conflict jeopardized $9.5 trillion of business in the world's most important commercial relationship. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Eddie Howe Clarifies Isak's Situation Ahead of Arsenal Clash
Eddie Howe confirms no contract talks with Swedish striker amid Liverpool links Eddie Howe Clarifies Isak's Situation Ahead of Arsenal Clash Newcastle United manager Eddie Howe's responded to swirling rumors surrounding the future of Alexander Isak denying any current negotiations over contract renewal with the Swedish forward. No Contract Talks Yet Speaking ahead of Newcastle's pre season friendly against Arsenal, Howe stated: "To my knowledge, there're no ongoing negotiations over Isak's contract. That could happen later" Despite Isak still having three years left on his deal speculation surged this week after the 25 year old missed the club's Asia tour due to reported thigh injury. Behind the Scenes Talks? Multiple outlets including The Athletic & Daily Mail, claim Isak's informed the club he wants clarity on possible move with Liverpool reportedly keen on his signature. However, Howe remained firm but diplomatic: "Isak's been amazing for the team. He's loved in the dressing room. We'd like him to continue his journey with us" He admitted Isak's under pressure: "He knows he'll be in the headlines daily. That's not easy for anyone in this position" €170M Price Tag Set Reports suggest Newcastle've placed 170 million Euro price tag on Isak an amount widely seen as deal breaker for potential buyers.
Yahoo
an hour ago
- Yahoo
Eli Lilly (LLY) Gains CHMP Approval for Donanemab in Alzheimer's Treatment
Eli Lilly recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a crucial therapeutic area. During the same period, LLY registered a 5% share price increase, notably outpacing the broader market's 1% rise over the past week. This uptrend in LLY's stock could be attributed to investors' optimism about donanemab's potential impact. Additionally, the company's collaboration with Gate Bioscience to develop novel therapies further strengthens its innovative capabilities, adding weight to its share price momentum amid broader market gains. We've spotted 2 risks for Eli Lilly you should be aware of, and 1 of them doesn't sit too well with us. Find companies with promising cash flow potential yet trading below their fair value. The recent positive opinion from the CHMP about Eli Lilly's Alzheimer's drug, donanemab, could significantly enhance the company's revenue and earnings forecasts. This development positions the company well for future growth, adding credibility to its strategic focus on expanding into high-demand therapeutic areas like oncology and immunology. Coupled with its collaboration with Gate Bioscience, these advances may provide substantial long-term benefits to the company's bottom line. Over the past five years, Eli Lilly's total return, which includes both share price growth and dividends, was a very large 473.44%. This long-term growth far outpaces the recent 1% rise in the broader market over the past year, bolstering investor confidence in the company's strategic trajectory and robust pipeline. In comparison to the US Pharmaceuticals industry, which saw a decline of 5.9% over the past year, Eli Lilly's sharp uptick in share price highlights its strong performance relative to industry peers. The company's earnings growth was a robust 80.9% over the past year, indicative of its potent execution in a challenging market. The current share price of US$812.69, when set against the analyst consensus price target of US$952.27, suggests there is room for potential growth. However, it also indicates investor caution, likely weighed down by concerns over competitive pressure and pricing dynamics. Investors might find reassurance in the company's ongoing manufacturing and R&D investments, which aim to mitigate risks and sustain growth in the coming years. Understand Eli Lilly's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LLY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
